Press Release|Articles|October 28, 2024
Camber Launches Generic Neurontin®
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Gabapentin Oral Solution, expanding its existing gabapentin product offerings.
- Indications include management of postherpetic neuralgia in adults and adjunctive therapy for partial onset seizures in patients aged three and older.
Advertisement
Piscataway, NJ, October 25, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line. Camber also offers Gabapentin Tablets and Capsules.
Gabapentin Oral Solution is indicated for:
- Management of Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
Gabapentin Oral Solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
To learn more about Gabapentin Oral Solution, please visit
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
3
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
4
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD
5